Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
Abroad (travel likely)RecruitingPHASE2
Conditions
Mild Cognitive Impairment · Early Alzheimer's Disease · AD-MCI
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Miami Department of Neurology, Miami, Florida, United States
Contact: Principal Investigator (Bernard S Baumel, MD)
Study leads
Bernard S. Baumel, MD
Principal Investigator
University of Miami